NCT01048580View on ClinicalTrials.gov

Study of Perifosine + Capecitabine for Colon Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

October 31, 2011

Conditions
Colon Cancer
Interventions
DRUG

Perifosine

Perifosine 50 mg orally once a day (Days 1-21)

DRUG

Capecitabine

Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
collaborator

SCRI Development Innovations, LLC

OTHER

lead

AEterna Zentaris

INDUSTRY